ReviewMaterials today. Bio2026
Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Biomechanics to Metallobiology: A Bibliometric Mapping of Ferroptosis and Trace Elements in Osteoarthritis (2014-2024).Biological trace element research · 2026Article
- Localization of the Complement C1q-Binding Site onTropical medicine and infectious disease · 2026Article
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Extensive studies have demonstrated that reactive oxygen species (ROS) play a critical role in the pathogenesis and progression of RA. Imbalanced ROS not only aggravate synovial inflammation and cartilage degradation but also disrupt immune homeostasis. In recent years, nanotechnology-based strategies for regulating ROS have provided new insights into the precise treatment of RA. This review systematically summarizes ROS-centered nanotherapeutic systems applied in RA therapy, including ROS-scavenging nanosystems, ROS-responsive nanosystems, ROS-scavenging and responsive composite nanosystems, and ROS-augmenting nanosystems. Furthermore, the review highlights the advantages of ROS-modulating nanosystems in reshaping the immune microenvironment, restoring redox balance, and achieving combination therapy and theranostic integration, while also addressing challenges related to biosafety, controllability, and clinical translation. Overall, programmable ROS-modulating nanotherapeutic strategies offer new directions and theoretical foundations for the precise treatment of RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.